Table 2 Treatment-emergent adverse events by first occurrence^a and verbatim term safety population

From: Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study

	Fish or krill Oil: 1.3 g/d
Verbatim term	Treatment A Ethyl Ester (N = 22)	Treatment B Triglycerides (N = 22)	Treatment C krill Oil (N = 22)
Abdominal bloating	0 (0.0 %)	1 (4.5 %)	0 (0.0 %)
Abdominal cramps	0 (0.0 %)	1 (4.5 %)	0 (0.0 %)
Abdominal pain	0 (0.0 %)	0 (0.0 %)	1 (4.5 %)
Hair loss	0 (0.0 %)	0 (0.0 %)	1 (4.5 %)
Headache	0 (0.0 %)	1 (4.5 %)	1 (4.5 %)
Insect bite	1 (4.5 %)	0 (0.0 %)	0 (0.0 %)
Intermittent epistaxis	0 (0.0 %)	0 (0.0 %)	1 (4.5 %)
Intermittent vasovagal	0 (0.0 %)	0 (0.0 %)	1 (4.5 %)
Nausea	2 (9.1 %)	0 (0.0 %)	0 (0.0 %)
Total events	3	3	5

^aSubjects may have had more than one adverse event. For these subjects, the first occurrence of the AE was tabulated

Back to article page